Contents

Preface

SECTION 1  INTRODUCTION TO MICROORGANISMS AND ANTIBACTERIAL CHEMOTHERAPY

1.1 Microorganisms
  Key points
    1.1.1 Classification
    1.1.2 Structure
    1.1.3 Antibacterial targets
    1.1.4 Bacterial detection and identification
    1.1.5 Other than its mode of action, what factors determine the antibacterial activity of a drug?
    1.1.6 Bacterial resistance
    1.1.7 The ‘post-antibiotic age’?
  References
  Questions

SECTION 2  AGENTS TARGETING DNA

2.1 Quinolone antibacterial agents
  Key points
    2.1.1 Discovery
    2.1.2 Synthesis
    2.1.3 Bioavailability
    2.1.4 Mode of action and selectivity
    2.1.5 Bacterial resistance
    2.1.6 Clinical applications
    2.1.7 Adverse drug reactions
    2.1.8 Drug interactions
    2.1.9 Recent developments
  References
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.3.7</td>
<td>Adverse drug reactions</td>
<td>223</td>
</tr>
<tr>
<td>4.3.8</td>
<td>Drug interactions</td>
<td>224</td>
</tr>
<tr>
<td>4.3.9</td>
<td>Recent developments</td>
<td>224</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>225</td>
</tr>
</tbody>
</table>

4.4 Chloramphenicol  
Key points  
4.4.1 Discovery  
4.4.2 Synthesis  
4.4.3 Bioavailability  
4.4.4 Mode of action and selectivity  
4.4.5 Bacterial resistance  
4.4.6 Clinical applications  
4.4.7 Adverse drug reactions  
4.4.8 Drug interactions  
4.4.9 Recent developments  
References  

4.5 Oxazolidinones  
Key points  
4.5.1 Discovery  
4.5.2 Synthesis  
4.5.3 Bioavailability  
4.5.4 Mode of action and selectivity  
4.5.5 Bacterial resistance  
4.5.6 Clinical applications  
4.5.7 Adverse drug reactions  
4.5.8 Drug interactions  
4.5.9 Recent developments  
References  

Questions  

SECTION 5 AGENTS TARGETING CELL-WALL SYNTHESIS  

5.1 β-Lactam antibiotics  
Key points  
5.1.1 Discovery  
5.1.2 Synthesis  
5.1.3 Bioavailability  
5.1.4 Mode of action and selectivity  
5.1.5 Bacterial resistance  
5.1.6 Clinical applications  
5.1.7 Adverse drug reactions  
5.1.8 Drug interactions  
5.1.9 Recent developments  
References  

x Contents
5.2 Glycopeptide antibiotics 305

Key points 305
5.2.1 Discovery 305
5.2.2 Synthesis 306
5.2.3 Bioavailability 307
5.2.4 Mode of action and selectivity 308
5.2.5 Bacterial resistance 309
5.2.6 Clinical applications 313
5.2.7 Adverse drug reactions 314
5.2.8 Drug interactions 316
5.2.9 Recent developments 316
References 317

5.3 Cycloserine 319

Key points 319
5.3.1 Discovery 319
5.3.2 Synthesis 320
5.3.3 Bioavailability 320
5.3.4 Mode of action and selectivity 321
5.3.5 Bacterial resistance 323
5.3.6 Clinical applications 323
5.3.7 Adverse drug reactions 325
5.3.8 Drug interactions 325
5.3.9 Recent developments 325
References 325

5.4 Isoniazid 327

Key points 327
5.4.1 Discovery 327
5.4.2 Synthesis 328
5.4.3 Bioavailability 329
5.4.4 Mode of action and selectivity 329
5.4.5 Bacterial resistance 330
5.4.6 Clinical applications 331
5.4.7 Adverse drug reactions 333
5.4.8 Drug interactions 334
5.4.9 Recent developments 335
References 335

5.5 Daptomycin 339

Key points 339
5.5.1 Discovery 339
5.5.2 Synthesis 340
5.5.3 Bioavailability 341
5.5.4 Mode of action and selectivity 341
<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.5.5  Bacterial resistance</td>
<td>343</td>
</tr>
<tr>
<td>5.5.6  Clinical applications</td>
<td>343</td>
</tr>
<tr>
<td>5.5.7  Adverse drug reactions</td>
<td>344</td>
</tr>
<tr>
<td>5.5.8  Drug interactions</td>
<td>345</td>
</tr>
<tr>
<td>5.5.9  Recent developments</td>
<td>345</td>
</tr>
<tr>
<td>References</td>
<td>346</td>
</tr>
<tr>
<td>Questions</td>
<td>349</td>
</tr>
<tr>
<td>Index</td>
<td>351</td>
</tr>
</tbody>
</table>